SCHEMBL20239264

SCHEMBL20239264

CS(=O)(=O)c1nc(CNC(=O)O)cc(Oc2ccc(CS(N)(=O)=O)cc2)n1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DGAT2 Q96PD7 1/20 0.45
ALDH1A1 P00352 3/20 0.36
LMNA P02545 3/20 0.36
GLA P06280 1/20 0.36
AKR1C3 P42330 1/20 0.35
KMT2A Q03164 2/20 0.34
GAA P10253 1/20 0.34
F2 P00734 1/20 0.34
SMN1; SMN2 Q16637 3/20 0.33
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33
MAPK8 P45983 1/20 0.33
MAPK9 P45984 1/20 0.33
GCK P35557 1/20 0.33
PDE4B Q07343 1/20 0.33
NPSR1 Q6W5P4 2/20 0.32
CYP1A2 P05177 2/20 0.32
CYP2C9 P11712 2/20 0.32
CYP2C19 P33261 2/20 0.32
TSHR P16473 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20259162 0.87 DGAT2 (0.42) DGAT2
SCHEMBL20239235 0.86 DGAT2 (0.44) DGAT2ALDH1A1LMNAGLAAKR1C3
SCHEMBL20239312 0.85 DGAT2 (0.47) DGAT2ALDH1A1LMNAGLAAKR1C3
SCHEMBL20239318 0.84 LMNA (0.45) DGAT2ALDH1A1LMNAGLAAKR1C3
SCHEMBL20239327 0.84 DGAT2 (0.44) DGAT2ALDH1A1LMNAGLAAKR1C3
SCHEMBL20259075 0.75 DGAT2 (0.43) DGAT2ALDH1A1KMT2ASMN1; SMN2NPC1
SCHEMBL18249768 0.73 DGAT2 (0.44) DGAT2ALDH1A1LMNAGLA
SCHEMBL20239303 0.73 DGAT2 (0.41) DGAT2LMNAKMT2ANPSR1TSHR
SCHEMBL20259248 0.73 DGAT2 (0.41) DGAT2MAPT
SCHEMBL16738665 0.72 DGAT2 (0.44) DGAT2ALDH1A1LMNAKMT2AF2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3298001-B1 DGAT2 INHIBITORS LILLY CO ELI (US) 2020-05-13 EP disclosed
US-10053429-B2 DGAT2 inhibitors ELI LILLY AND COMPANY (US) 2018-08-21 US disclosed
US-20180162825-A1 NOVEL DGAT2 INHIBITORS ELI LILY AND COMPANY (US) 2018-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180162825-A1 NOVEL DGAT2 INHIBITORS DGAT2, DGAT1, LCAT DGAT2 1/4885ALDH1A1 1430/4885LMNA 2022/4885
US-10053429-B2 DGAT2 inhibitors DGAT2, DGAT1, LCAT DGAT2 1/4885ALDH1A1 1189/4885LMNA 1722/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.